Skyhawk Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 85

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $7.5M

  • Investors
  • 19

Skyhawk Therapeutics General Information

Description

Developer of small-molecule RNA-modulating therapies designed to treat diseases with limited treatment options. The company offers its proprietary SKYSTAR platform to discover and develop small-molecule therapies that modulate RNA, enabling the development of treatments for diseases that are difficult to address through existing therapeutic approaches.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 180 3rd Avenue
  • Sixth Floor
  • Waltham, MA 02451
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 180 3rd Avenue
  • Sixth Floor
  • Waltham, MA 02451
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Skyhawk Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 13-May-2026 $7.5M Completed Generating Revenue
4. Later Stage VC 06-Jul-2022 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 30-Jun-2021 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jan-2019 $100M $108M Completed Pre-Clinical Trials
1. Seed Round 23-Jan-2018 $8M $8M Completed Pre-Clinical Trials
To view Skyhawk Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Skyhawk Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule RNA-modulating therapies designed to treat diseases with limited treatment options. The comp
Drug Discovery
Waltham, MA
85 As of 2026

Cambridge, MA
 

Shelton, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Skyhawk Therapeutics Competitors (21)

One of Skyhawk Therapeutics’s 21 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Nanoviricides Corporation Shelton, CT
Remix Therapeutics Venture Capital-Backed Watertown, MA
Arcturus Therapeutics Holdings Formerly VC-backed San Diego, CA
Spark Therapeutics Formerly VC-backed Philadelphia, PA
You’re viewing 5 of 21 competitors. Get the full list »

Skyhawk Therapeutics Patents

Skyhawk Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026148020-A1 Formulations for use in modulating rna splicing and methods of making and using the same Pending 31-Dec-2024
WO-2026101897-A9 6-(6-(((lr,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1jnonan-3yl) (methyl)amino)pyridazine-3-yl)-2-methylbenzo[d]oxazol-5-ol to treat huntington's disease Pending 05-Nov-2024
WO-2026101897-A1 6-(6-{[(1r,2r,3s,5s)-2-fluoro-8-azabicyclo[3.2.1 ]octan-3-yl] (methyl)amino }pyridazin-3-yl)-2-methyl-l,3-benzoxazol-5-ol to treat huntington's disease Pending 05-Nov-2024
WO-2026019893-A1 Compositions useful for modulating splicing Pending 17-Jul-2024
WO-2026019914-A1 Compositions useful for modulating splicing Pending 17-Jul-2024 C07D487/04
To view Skyhawk Therapeutics’s complete patent history, request access »

Skyhawk Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Skyhawk Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
ABRDN Emerging Markets Equity Income Asset Manager Minority
Tekla World Healthcare Fund Asset Manager Minority
Hongsen Investment Venture Capital Minority
Sanofi Ventures Corporate Venture Capital Minority
Sphera Funds Management Hedge Fund Minority
You’re viewing 5 of 19 investors. Get the full list »

Skyhawk Therapeutics FAQs

  • When was Skyhawk Therapeutics founded?

    Skyhawk Therapeutics was founded in 2015.

  • Where is Skyhawk Therapeutics headquartered?

    Skyhawk Therapeutics is headquartered in Waltham, MA.

  • What is the size of Skyhawk Therapeutics?

    Skyhawk Therapeutics has 85 total employees.

  • What industry is Skyhawk Therapeutics in?

    Skyhawk Therapeutics’s primary industry is Drug Discovery.

  • Is Skyhawk Therapeutics a private or public company?

    Skyhawk Therapeutics is a Private company.

  • What is Skyhawk Therapeutics’s current revenue?

    The current revenue for Skyhawk Therapeutics is .

  • How much funding has Skyhawk Therapeutics raised over time?

    Skyhawk Therapeutics has raised $304M.

  • Who are Skyhawk Therapeutics’s investors?

    ABRDN Emerging Markets Equity Income, Tekla World Healthcare Fund, Hongsen Investment, Sanofi Ventures, and Sphera Funds Management are 5 of 19 investors who have invested in Skyhawk Therapeutics.

  • Who are Skyhawk Therapeutics’s competitors?

    Sarepta Therapeutics, Nanoviricides, Remix Therapeutics, Arcturus Therapeutics Holdings, and Spark Therapeutics are some of the 21 competitors of Skyhawk Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process